EpilepsyGTx Ltd, a biotech developing gene therapies to treat refractory epilepsy, has appointed Dimitri Kullmann as chief scientific officer. Professor Kullmann, a co-founder of EpilepsyGTx, will shape and execute scientific strategy, set research priorities and oversee the delivery of pipeline programmes. He is Professor of Neurology in the Department of Epilepsy at the University College London Institute of Neurology, UK, where he leads the experimental epilepsy group. He brings 27 years of experience as a consultant neurologist at the National Hospital for Neurology and Neurosurgery.
Prof Kullmann has an MD in medicine and a DPhil in neuroscience from the University of Oxford. In 1992, he established his own laboratory at the Institute of Neurology, for synaptic research, served as editor-in-chief of the neurology journal Brain from 2014 to 2020, and is a fellow of the Academy of Medical Sciences and of the Royal Society.
EpilepsyGTx announced the appointment on 29 April 2026.
Copyright 2026 Evernow Publishing Ltd.